Menu Menu

FEVER-PGx: Pharmacogenomic Study of the Felodipine Event Reduction

FEVER was a prospective multicenter double-blind randomized parallel group trial conducted in Chinese patients aged 50-79 with one or two additional CV risk factors whose SBP was between 140-180 mmHg and DBP 90-100 mmHg 6 weeks after switching from their previous antihypertensive therapy to 12.5 mg of HCTZ. Participants were then randomized to receive felodipine ER or placebo to compare the incidence of stroke and other CV events for 24 months. The authors found that stroke and other CV events were significantly reduced in the felodipine group. DNA samples are available for 600 participants.